Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer

Gastrointestinal Cancer

FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306

Eur J Cancer

Holch JW, Ohnmacht AJ, Stintzing S, Heinrich K, Weiss L, Probst V, Stahler A, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Heintges T, Kahl C, Kullmann F, Link H, Höffkes HG, Moehler M, Modest DP, Menden MP, Heinemann V

doi: 10.1016/j.ejca.2025.115388

Gastrointestinal Cancer

Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE

Int J Cancer

Potthoff K, Uhlig J, Jacobasch L, Müller L, Reiser M, de Buhr R, Polata S, Gerger A, Zehrer V, Amann A, Göhler T, Serrer L, Schröder J, Semsek D, Köhler A, Stübs P, Prager G, Siebenbach HU, Schuch A, Marschner N

doi: 10.1002/ijc.70139

Gastrointestinal Cancer

Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO

Ann Oncol

Germani MM, Heinemann V, Rossini D, Fischer von Weikersthal L, Pietrantonio F, Heinrich K, Stahler A, Lonardi S, Kaiser F, Decker T, Salvatore L, Weiss L, Morano F, Fuchs M, Bergamo F, Antoniotti C, Masi G, Stintzing S, Frumento P, Cremolini C, Modest DP

doi: 10.1016/j.annonc.2025.08.001

Gastrointestinal Cancer

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials

Eur J Cancer

Antoniotti C, Marmorino F, Rossini D, Schmoll HJ, Lonardi S, Tonini G, Borelli B, Cupini S, Stein A, Moretto R, Bergamo F, Ronzoni M, Germani MM, Zaniboni A, Fazio R, De Grandis MC, Ongaro E, Masi G, Cremolini C

doi: 10.1016/j.ejca.2025.115713

Skin Cancer

First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG

Eur J Cancer

Reinhard S, Utikal JS, Zaremba A, Lodde G, von Wasielewski I, Klespe KC, Meier F, Haferkamp S, Kähler KC, Herbst R, Gebhardt C, Sindrilaru A, Dippel E, Angela Y, Mohr P, Pfoehler C, Forschner A, Kaatz M, Schell B, Gesierich A, Loquai C, Hassel JC, Ulrich J, Meiss F, Schley G, Heinzerling LM, Sachse M, Welzel J, Weishaupt C, Sunderkötter C, Michl C, Lindhof HH, Kreuter A, Heppt MV, Wenk S, Mauch C, Berking C, Nedwed AS, Gutzmer R, Leiter U, Schadendorf D, Ugurel S, Weichenthal M, Haist M, Fleischer MI, Lang B, Grabbe S, Stege H

doi: 10.1016/j.ejca.2025.115356

Gastrointestinal Cancer

Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study

Eur J Cancer

Kamp D, May AM, Adenis A, Capela A, Derks S, De Felice F, Dovnik NF, Hierro C, Ilhan-Mutlu A, Lordick F, Obermannova RL, Petrillo A, Puccini A, Raimundo A, Roviello G, Siebenhüner A, Slingerland M, Smyth EC, van Laarhoven HWM, Mohammad NH

doi: 10.1016/j.ejca.2025.115278

Lung, Respiratory and Thoracic Cancer

Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study

Lung Cancer

Uprety D, Abrahami D, Marcum ZA, Li B, Sang A, Davis M, Rifi N, Kelton JM, Ramaswamy K, Sanghvi P, Bazhenova L

doi: 10.1016/j.lungcan.2025.108436

Gastrointestinal Cancer

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort

Int J Cancer

van Nassau SCMW, Zwart K, van der Baan FH, Vink GR, Elferink MAG, Snaebjornsson P, May AM, Koopman M, Roodhart JML

doi: 10.1002/ijc.35410

Gastrointestinal Cancer

Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis

Cancer Treat Rev

Holz A, Paul B, Zapf A, Pantel K, Joosse SA

doi: 10.1016/j.ctrv.2025.102999

Related content

FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306

Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE

Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials

First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG

Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study

Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort

Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis